On November 19, 2022 MonTa Biosciences reported that the company has transitioned from a preclinical to a Clinical stage Biotech company (Press release, MonTa Biosciences, NOV 19, 2020, View Source [SID1234618638]). MonTa has today filed our first Clinical Trial Application in Europe and look forward to start treatment of the first patient with our lead candidate MBS8, in Q1, 2021. We will start the dose-escalation part of the study with two Danish sites and later expand into additional European sites. The trail will include MBS8 dosed in monotherapy and focus on safety, biomarkers and effect on tumor development. MBS8 is a novel TLR7 agonist formulated in micelles that show a strong antitumor activity, superior to other TLR7 agonists due to a different Mode of Action involving immediate migration of innate immune cells into tumor tissue and killing of tumor cells within hours. The Phase I trial is designed with two stages, stage I with a dose escalation phase and stage II with an expansion phase at the recommended phase 2 dose level.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!